OTCMKTS:STXS - Stereotaxis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.86 -0.01 (-1.15 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$0.8699
Today's Range$0.80 - $0.8625
52-Week Range$0.51 - $1.10
Volume53,852 shs
Average Volume27,543 shs
Market Capitalization$50.14 million
P/E RatioN/A
Dividend YieldN/A
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

Receive STXS News and Ratings via Email

Sign-up to receive the latest news and ratings for STXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Electromedical equipment


Debt-to-Equity RatioN/A
Current Ratio1.72
Quick Ratio1.60


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$31.14 million
Price / Sales1.63
Cash Flow$0.0876 per share
Price / Cash9.82
Book Value($1.16) per share
Price / Book-0.74


EPS (Most Recent Fiscal Year)N/A
Net Income$-5,880,000.00
Net Margins-18.08%
Return on Equity-8.52%
Return on Assets9.14%


Outstanding Shares58,980,000
Market Cap$50.14

The Truth About Cryptocurrencies

Stereotaxis (OTCMKTS:STXS) Frequently Asked Questions

What is Stereotaxis' stock symbol?

Stereotaxis trades on the OTCMKTS under the ticker symbol "STXS."

How were Stereotaxis' earnings last quarter?

Stereotaxis Inc (OTCMKTS:STXS) announced its earnings results on Monday, May, 14th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter. The medical equipment provider earned $6.97 million during the quarter. Stereotaxis had a negative return on equity of 8.52% and a negative net margin of 18.08%. View Stereotaxis' Earnings History.

When is Stereotaxis' next earnings date?

Stereotaxis is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Stereotaxis.

What is the consensus analysts' recommendation for Stereotaxis?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Stereotaxis' key competitors?

Who are Stereotaxis' key executives?

Stereotaxis' management team includes the folowing people:
  • Mr. David Leo Fischel CFA, CPA, Chairman & CEO (Age 31)
  • Mr. Martin C. Stammer, Chief Financial Officer (Age 38)
  • Ms. Karen Witte Duros, Sr. VP, Gen. Counsel, Compliance Officer and Sec. (Age 63)
  • Dr. Gery Tomassoni M.D., FHRS, Chief Medical Officer
  • Dr. J. David Burkhardt M.D., F.A.C.C., Chief Devel. Advisor

Has Stereotaxis been receiving favorable news coverage?

News articles about STXS stock have trended somewhat positive on Tuesday, Accern reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stereotaxis earned a media sentiment score of 0.02 on Accern's scale. They also assigned news articles about the medical equipment provider an impact score of 46.63 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Stereotaxis?

Shares of STXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stereotaxis' stock price today?

One share of STXS stock can currently be purchased for approximately $0.86.

How big of a company is Stereotaxis?

Stereotaxis has a market capitalization of $50.14 million and generates $31.14 million in revenue each year. Stereotaxis employs 117 workers across the globe.

How can I contact Stereotaxis?

Stereotaxis' mailing address is 4320 FOREST PARK AVENUE, ST.LOUIS MO, 63108. The medical equipment provider can be reached via phone at 314-678-6100 or via email at [email protected]

MarketBeat Community Rating for Stereotaxis (OTCMKTS STXS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  135
MarketBeat's community ratings are surveys of what our community members think about Stereotaxis and other stocks. Vote "Outperform" if you believe STXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.